Corrigendum to "Outcomes of Living Kidney Donors Following Donor Nephrectomy in Aotearoa New Zealand" [Volume 10, Issue 3, March 2025, Pages 762-771].
「更正啟事：Aotearoa New Zealand 活體腎臟捐贈者於捐腎手術後之預後分析」【第10卷，第3期，2025年3月，頁762-771】
Kidney Int Rep 2025-06-09
Corrigendum to "Safety and efficacy of semaglutide in post kidney transplants patients with type 2 diabetes or post-transplant diabetes" [J. Clin. Translat. Endoc. 36C (2024) 100343].
對於「Safety and efficacy of semaglutide in post kidney transplants patients with type 2 diabetes or post-transplant diabetes」的更正 [J. Clin. Translat. Endoc. 36C (2024) 100343]。
J Clin Transl Endocrinol 2025-01-07
Corrigendum to "Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia" [<i>Kidney International Reports</i> Volume 9, Issue 5, May 2024, Pages 1419-1428].
對於「Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia」的更正 [<i>Kidney International Reports</i> 第9卷，第5期，2024年5月，頁1419-1428]。
Kidney Int Rep 2025-02-24
Corrigendum to "POS-074 SERUM NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN, EARLY BIOMARKER OF ACUTE KIDNEY INJURY IN ASPHYXIATED TERM NEONATES AT LAGOS STATE UNIVERSITY TEACHING HOSPITAL" [<i>Kidney International Reports</i> Volume 7, Issue 2, Supplement, February 2022, Page S31].
對於「POS-074 SERUM NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN, EARLY BIOMARKER OF ACUTE KIDNEY INJURY IN ASPHYXIATED TERM NEONATES AT LAGOS STATE UNIVERSITY TEACHING HOSPITAL」的更正 [<i>Kidney International Reports</i> 第7卷，第2期，補充，2022年2月，第S31頁]。
Kidney Int Rep 2025-02-24
Corrigendum to "WCN25-3808 NAFLD IN ESRD - PREVALENCE OF NAFLD in ESRD PATIENTS AND EVALUATION OF THERAPEUTIC EFFICACY OF TOCOTRIENOL IN TREATMENT OF NAFLD" [<i>Kidney International Reports</i> Volume 10, Issue 2, Supplement, February 2025, Pages S339-S340].
更正啟事：「WCN25-3808 末期腎臟病（ESRD）中的非酒精性脂肪肝病（NAFLD）—ESRD 患者中 NAFLD 的盛行率及 tocotrienol 治療 NAFLD 療效之評估」[《Kidney International Reports》2025年2月，第10卷，第2期，增刊，S339-S340頁]
Kidney Int Rep 2025-04-30
Corrigendum to "Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy" [Volume 10, Issue 1, January 2025, Pages 217-226].
更正啟事：「ALIGN 隨機對照研究 Atrasentan 用於 IgA Nephropathy 患者之研究設計與基線特徵」[第10卷，第1期，2025年1月，頁217-226]
Kidney Int Rep 2025-04-30
重點摘要：
這則通知是用來更正 DOI 為 10.1016/j.ekir.2024.10.004 的文章。內容很可能是針對該篇發表的錯誤進行修正，或是提供相關的最新更新。
PubMedDOI
Correction to: The ERA Registry Annual Report 2022: Epidemiology of Kidney Replacement Therapy in Europe, with a focus on sex comparison.
更正：ERA Registry 2022 年度報告：歐洲腎臟替代治療流行病學，聚焦性別比較
Clin Kidney J 2025-05-07
Corrigendum to "PREGNANCY AS A WINDOW TO CURRENT AND FUTURE KIDNEY HEALTH-AN OPPORTUNITY" [Volume 10, Issue 3, March 2025, Pages 645-649].
「PREGNANCY AS A WINDOW TO CURRENT AND FUTURE KIDNEY HEALTH-AN OPPORTUNITY」[第10卷，第3期，2025年3月，第645-649頁]之更正啟事
Kidney Int Rep 2025-06-09
Corrigendum to "SAT-040 RENAL SAFETY OF DIRECT ACTING ANTIVIRAL DRUGS IN POST LIVER TRANSPLANT PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION" [Volume 5, Issue 3, Supplement, March 2020, Pages S18-S19].
「SAT-040 直接作用型抗病毒藥物於肝臟移植後慢性 C 型肝炎患者之腎臟安全性」更正啟事 [第5卷，第3期，增刊，2020年3月，S18-S19頁]
Kidney Int Rep 2025-06-09
Erratum to "Advancing Understanding of Mitochondrial Function in Diabetic Kidney Disease" [<i>Kidney International Reports</i> Volume 10, Issue 2, February 2025, Pages 285-286].
「更正啟事：『推進對糖尿病腎病變中線粒體功能的理解』［Kidney International Reports 第10卷第2期，2025年2月，頁285-286］」
Kidney Int Rep 2025-07-09
這則通知是針對 DOI 10.1016/j.ekir.2024.12.001 的文章做更正，主要是修正原文的錯誤或補充最新資訊。詳細內容請直接參考該篇文章的更正說明。
PubMedDOI